Results 51 to 60 of about 7,605 (170)

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, Volume 117, Issue 8, Page 2064-2084, August 2026.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source

Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
Rana R. McKay, Wanling Xie, Archana Ajmera, Arlene Araneta, Edmund Folefac, Arif Hussain, Christos E. Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, Geoffrey I. Shapiro   +11 more
wiley   +1 more source

Splitting of the Ribose-Ribose Linkage of Poly(Adenosine Diphosphate-Ribose) by a Calf Thymus Extract

Journal of Biological Chemistry, 1971
Abstract Poly(ADP-Rib) was hydrolyzed by a calf thymus nuclear preparation. The reaction products were ADP-Rib and oligo(ADP-Rib). This reaction is a novel mechanism for degradation of poly(ADP-Rib).
M, Miwa, T, Sugimura
openaire   +2 more sources

Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer

International Journal of Cancer, Volume 159, Issue 1, Page 257-268, 1 July 2026.
What's New? Epithelial ovarian cancer (EOC) is a severe malignancy with few effective treatment options. While the mechanisms remain unclear, changes in lipid metabolism may fuel tumor growth and EOC progression, offering a possible path for new treatments.
Hitomi Sakaguchi‐Mukaida, Kosuke Hiramatsu, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Tadashi Iwamiya, Shinya Matsuzaki, Tetsuji Naka, Yutaka Ueda, Tadashi Kimura, Michiko Kodama   +10 more
wiley   +1 more source

Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer

Therapeutic Advances in Medical Oncology
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have significantly improved the treatment of advanced ovarian cancer, however, there are still many aspects of their use that require further understanding.
Uma A. Mukherjee, Rowan E. Miller, Jonathan A. Ledermann   +2 more
doaj   +1 more source

Intraoperative Collection of Ascitic Fluid With Intra‐ or Postoperative Reinfusion in Ovarian Cancer: Safety and Feasibility of a Roller Pumping Method

Therapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 371-376, June 2026.
ABSTRACT Introduction Patients with ovarian cancer often present with massive ascites, leading to significant protein loss during surgical procedures. Although cell‐free concentrated ascites reinfusion therapy (CART) is used in palliative settings to mitigate protein loss, its application in intraoperative settings remains unexplored.
Yutaka Yoneoka, Tsukuru Amano, Akimasa Takahashi, Mari Deguchi, Hiroyuki Yamanaka, Yuji Tanaka, Shunichiro Tsuji, Takashi Murakami   +7 more
wiley   +1 more source

First-line treatment of advanced ovarian cancer: an expert update

Libri Oncologici, 2020
Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy.
Branka Petrić-Miše
doaj   +1 more source

Bovine thymus poly(adenosine diphosphate ribose) polymerase.

Journal of Biological Chemistry, 1978
About 1,300-fold purification of poly(adenosine diphosphate ribose) polymerase has been achieved from the extract of bovine thymus with a recovery of 10 to 20%. The final preparation has a purity of 99%, and the enzyme is composed of a single peptide with a molecular weight of 130,000. The purified enzyme required NAD+, Mg2+, a thiol compound, DNA, and
K, Yoshihara, T, Hashida, Y, Tanaka, H, Ohgushi, H, Yoshihara, T, Kamiya   +5 more
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, Volume 20, Issue 6, Page 1453-1472, June 2026.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Enzymatic Synthesis of NAD+

Current Protocols, Volume 6, Issue 6, June 2026.
Abstract Nicotinamide adenine dinucleotide (NAD+) is an essential metabolite involved in numerous biological processes, functioning both as a redox cofactor in cellular energy metabolism and as a co‐substrate for NAD+‐utilizing enzymes, including sirtuins and poly(ADP‐ribose) polymerases.
Emily Boyle, Olivia Zhang, Yana Cen
wiley   +1 more source